Table 3. Demographic characteristics of matched samples for analysis of SARS-CoV-2 vaccine effectiveness, Western Australia, Australia, February 1–May 31, 2022*.

Characteristic	Unvaccinated, no. (%), n = 30,420	Two doses, no. (%), n = 84,237	Three doses, no. (%), n = 263,243	Total, no. (%), n = 377,900
Age group, y
16–19	1,470 (4.8)	13,645 (16.2)	14,451 (5.5)	29,566 (7.8)
20–29	9,851 (32.4)	28,569 (33.9)	50,886 (19.3)	89,306 (23.6)
30–39	9,083 (29.9)	20,395 (24.2)	58,914 (22.4)	88,392 (23.4)
40–49	4,294 (14.1)	11,672 (13.9)	58,712 (22.3)	74,678 (19.8)
50–59	2,519 (8.3)	5,709 (6.8)	42,446 (16.1)	50,674 (13.4)
60–69	1,646 (5.4)	2,517 (3.0)	21,903 (8.3)	26,066 (6.9)
70–79	849 (2.8)	932 (1.1)	9,577 (3.6)	11,358 (3.0)
>80	708 (2.3)	798 (0.9)	6,354 (2.4)	7,860 (2.1)
Sex
F	14,180 (46.6)	40,940 (48.6)	144,180 (54.8)	199,300 (52.7)
M	15,972 (52.5)	43,143 (51.2)	118,699 (45.1)	177,814 (47.1)
Unspecified	268 (0.9)	154 (0.2)	364 (0.1)	786 (0.2)
Aboriginal Status
Non-Aboriginal	29,367 (96.5)	80,418 (95.5)	259,701 (98.7)	369,486 (97.8)
Aboriginal	1,053 (3.5)	3,819 (4.5)	3,542 (1.3)	8,414 (2.2)
No. comorbidities
0	29,269 (96.2)	80,583 (95.7)	246,896 (93.8)	356,748 (94.4)
1	221 (0.7)	852 (1.0)	3,929 (1.5)	5,002 (1.3)
2	596 (2.0)	2,046 (2.4)	9,008 (3.4)	11,650 (3.1)
3	46 (0.2)	120 (0.1)	778 (0.3)	944 (0.2)
4	195 (0.6)	404 (0.5)	1,815 (0.7)	2,414 (0.6)
>5	93 (0.3)	229 (0.3)	817 (0.3)	1,142 (0.3)
IRSAD
1	345 (1.1)	390 (0.5)	515 (0.2)	1,250 (0.3)
2	2,090 (6.9)	5,893 (7.0)	12,425 (4.7)	20,408 (5.4)
3	658 (2.2)	2,242 (2.7)	5,636 (2.1)	8,536 (2.3)
4	2,893 (9.5)	9,375 (11.1)	24,962 (9.5)	37,230 (9.9)
5	2,649 (8.7)	9,784 (11.6)	26,867 (10.2)	39,300 (10.4)
6	3,446 (11.3)	9,734 (11.6)	25,666 (9.8)	38,846 (10.3)
7	3,296 (10.8)	10,479 (12.4)	28,123 (10.7)	41,898 (11.1)
8	3,967 (13.0)	13,371 (15.9)	39,974 (15.2)	57,312 (15.2)
9	6,186 (20.3)	13,719 (16.3)	51,589 (19.6)	71,494 (18.9)
10	4,890 (16.1)	9,250 (11.0)	47,486 (18.0)	61,626 (16.3)

*IRSAD, Index of Relative Socioeconomic Advantage and Disadvantage.